Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 387-390

  Thill, Marc ^a   Fischer, Dorothea ^a   Kelling, Katharina ^a   Hoellen, Friederike ^a   Dittmer, Christine ^a   Hornemann, Amadeus ^a   Salehin, Darius ^b   Diedrich, Klaus ^a   Friedrich, Michael ^b   Becker, Steffi ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Helios Hospital Krefeld   (Germany)

Author keywords

15 Hydroxyprostaglandin dehydrogenase; 25 Hydroxycholecalciferol; Cyclooxygenase 2; Ovarian cancer; Prostaglandin E2; Vitamin D receptor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCIFEDIOL; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; VITAMIN D RECEPTOR; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCITRIOL RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; VITAMIN BLOOD LEVEL; WESTERN BLOTTING; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; OVARY; OVARY TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALCIFEDIOL; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; RECEPTORS, CALCITRIOL;

EID: 77954758969     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.049     Document Type: Article

References (15)

1. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F., Maggiano N., Gessi M., Mancuso S., Ranelletti F.O., Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. Oncol. 2002, 13(8):1205-1211.
2. Fujimoto J., Toyoki H., Sakaguchi H., Jahan I., Alam S.M., Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol. Rep. 2006, 15(1):21-25.
3. Yoshida A., Sarian L.O., Andrade L.A., Pignataro F., Pinto G.A., Derchain S.F. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int. J. Gynecol. Cancer 2007, 17(3):607-614.
4. Rask K., Zhu Y., Wang W., Hedin L., Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol. Cancer 2006, 5:62.
5. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005, 289(1):F8-28.
6. Malloy P.J., Pike J.W., Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev. 1999, 20(2):156-188.
7. Moreno J., Krishnan A.V., Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol. 2005, 97(1-2):31-36.
8. Thill M., Fischer D., Becker S., Cordes T., Dittmer C., Diedrich K., Salehin D., Friedrich M. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res. 2009, 29(9):3619-3625.
9. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., Siegert A., Reles A., Klosterhalfen B., Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 2002, 160(3):893-903.
10. Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., Goodman M.T. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol. Biomarkers Prev. 2007, 16(12):2566-2571.
11. 3-24-hydroxylase in benign and malignant ovarian cell lines and tissue. Anticancer Res. 2009, 29(9):3635-3640.
12. Fischer D., Thomé M., Becker S., Cordes T., Diedrich K., Friedrich M., Thill M. 25-Hydroxyvitamin D3 1α-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res. 2009, 29(9):3627-3634.
13. Toriola A.T., Surcel H.M., Agborsangaya C., Grankvist K., Tuohimaa P., Toniolo P., Lukanova A., Pukkala E., Lehtinen M. Serum 25-hydroxyvitamin D and risk of ovarian cancer. Eur. J. Cancer 2009, [Epub ahead of print].
14. Chang C.L., Ma B., Pang X., Wu T.C., Hung C.F. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol. Ther. 2009, 17(8):1365-1372.
15. Zhang X., Jiang F., Li P., Li C., Ma Q., Nicosia S.V., Bai W.W. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin. Cancer Res. 2005, 11(1):323-328.